1. Calvo-Aller E, Baselga J, Glatt S, Cleverly A, Lahn M, Arteaga CL, Rothenberg ML, Carducci MA. First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase. J Clin Oncol 2008;26 (suppl):Abstr# 14554.
2. Derynck R, Miyazono K. TGF-β and the TGF-β family. In: Derynck R, Miyazono K, editors. The TGF-β family. New York: Cold Spring Harbor Laboratories Press/Cold Spring Harbor; 2008. p. 29–44.
3. Goff LW, De Braud FG, Cohen RB, Berlin J, Noberasco C, Borghaei H, Wang E, Hu Lowe D, Levin WJ, Gallo-Stampino C. Phase I study of PF-03446962, a fully human mab against ALK1, a TGFβ receptor involved in tumor angiogenesis. J Clin Oncol 2010;28 (suppl):Abstr# 3034.
4. Hsu FJ, Teicher BA, McPherson JM. Rationale for anti-TGF-b antibody therapy in oncology. In: Jakowlew SB, editor. Transforming growth factor –β in cancer therapy, vol. II. Totowa: Humana Press Inc; 2008. p. 757–74. ISBN II.
5. Jakowlew SB. Component hardware for ttransforming growth factor-β signal transduction: TGF-β ligands, TGF-β receptors and Smads. In: Jakowlew SB, editor. Transforming growth factor –β in cancer therapy, vol. I. Totowa: Humana Press Inc; 2008. p. 3–22.